| Date | Time | Source | |
| 05/07/2013 | 7:40AM | ZACKS | Wider-than-Expected Loss at Corcept - Analyst Blog
Corcept Therapeutics Inc. (CORT) posted a loss per share of 11 cents in the first quarter of 2013, wider than the Zacks Consensus Estimate of a loss of 10 cents. In the year-ago quarter, Corcept reported a loss of 13 cents. Corcept generated revenues of $1.7 million in the first quarter of 2013, missing the Zacks Consensus... More...>> |
| 05/02/2013 | 4:05PM | MWUS | Corcept Therapeutics Announces First Quarter 2013 Financial Results
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financial results for the quarter ended March 31, 2013. First Quarter Financial Results For... More...>> |
| 04/26/2013 | 9:00AM | MWUS | Corcept Therapeutics to Announce First Quarter 2013 Financial Results and Host Conference Call
Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter 2013 financial results on May 2, 2013. The Company will host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time). Conference Call Information To participate, dial 1-888-771-4371 from the United States... More...>> |
| 03/14/2013 | 9:48AM | ZACKS | Corcept's Loss Narrows in 4Q - Analyst Blog
Corcept Therapeutics Inc. (CORT) posted a loss per share of 11 cents in the fourth quarter of 2012 which was narrower than the loss of 12 cents posted in the year-ago quarter Adjusted loss per share was 10 cents (including stock-based compensation but excluding accretion of interest expense related to long-term obligation... More...>> |
| 03/07/2013 | 5:01PM | MWUS | Corcept Therapeutics Announces Fourth Quarter and Full Year 2012 Financial Results
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financial results for the fourth quarter and full year ended December 31, 2012. In April 2012... More...>> |
| 02/15/2013 | 12:05PM | ZACKS | Corcept Provides 4Q & 2012 Outlook - Analyst Blog
Corcept Therapeutics Inc. (CORT) recently released preliminary results for the fourth quarter and full year 2012. Corcept expects fourth quarter revenues to come around $1.4 million, up 27.3% from the third quarter. Revenues for 2012 are projected at $3.3 million. Corcept expects to end 2012 with a cash balance of $93.0... More...>> |
| 02/12/2013 | 4:05PM | MWUS | Corcept Therapeutics Announces Fourth Quarter and Full Year Revenue and Corporate Update
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its unaudited net revenue for the quarter and the year ended December 31, 2012 and cash balance... More...>> |
| 01/23/2013 | 8:20AM | MWUS | Merger and Acquisition Activity Expected to Rise in 2013 as Big Pharma Companies Flush With Cash
Lost revenues from expiring patents has played a major part in the Biotech Industry's success in recent years. A total of 676 takeovers of biotechnology and pharmaceutical companies have occurred in the past three years, with an average premium of 38 percent, according to data collected by Bloomberg. Five Star Equities... More...>> |
| 01/23/2013 | 8:00AM | PRNUS | Behind The Success - Research Report on Corcept Therapeutics Inc. and Dyax Corp.
Behind The Success - Research Report on Corcept Therapeutics Inc. and Dyax Corp. Behind The Success - Research Report on Corcept Therapeutics Inc. and Dyax Corp. Biotech firms Corcept and Dyax have each risen to the occasion with their innovative solutions for unmet medical needs, both having gained substantial momentum... More...>> |
| 01/07/2013 | 8:45AM | MWUS | Free Research Reports on CORT, CUR, EXM and SVU Issued by the Bedford Report
The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country. Corcept Therapeutics Inc. (NASDAQ: CORT) shares gained 15 percent on over 1.6 million shares traded... More...>> |
| 12/10/2012 | 8:45AM | MWUS | Free Research Reports on AVGO, CMTL, CORT and LNG Issued by the Bedford Report
The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country. Avago Technologies Ltd. (NASDAQ: AVGO) shares of the semiconductor company declined on 8.5 million... More...>> |
| 12/10/2012 | 8:00AM | MWUS | The Reason It Trades, What's Moving PPHM, CORT, CTIC and ACTC
Moments ago, GainHunter.com released another issue of its world-class newsletter in which it took time to review and explain some of the most talked about situations on wall street today. Give yourself an advantage in today's market. In order to become successful, you need to have information as it happens and understand... More...>> |
| 12/07/2012 | 8:00AM | MWUS | Perfect Trade Setups, How to Play PPHM, CORT, CTIC and ACTC
Moments ago, GainHunter.com released another issue of its world-class newsletter in which it took time to review and explain some of the most talked about situations on wall street today. Give yourself an advantage in today's market. In order to become successful, you need to have information as it happens and understand... More...>> |
| 12/06/2012 | 8:37AM | MWUS | The Real Story Behind UEPS, CORT, ACLS and ASYS
Moments ago, GainHunter.com released another issue of its world-class newsletter in which it took time to review and explain some of the most talked about situations on wall street today. Give yourself an advantage in today's market. In order to become successful, you need to have information as it happens and understand... More...>> |
| 12/06/2012 | 8:20AM | MWUS | Higher Rate of FDA New Drug Approvals a Major Factor in Biotech Industry's Success in 2012
The Biotech Industry has skyrocketed in 2012 as an increase in the number of new drug approvals has boosted investor optimism within the industry. The iShares Nasdaq Biotechnology Index Fund (IBB) and the SPDR S&P Biotech ETF (XBI) have both gained over 25 percent year-to-date. Five Star Equities examines the outlook for... More...>> |
| 11/09/2012 | 8:45AM | MWUS | Free Research Reports on CENX, CORT, DVR and IQNT Issued by the Bedford Report
The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country. Century Aluminum Co. (NASDAQ: CENX) shares of the aluminum producer have fallen sharply this week... More...>> |
| 10/31/2012 | 4:05PM | MWUS | Corcept Therapeutics Announces Third Quarter Results and Corporate Update
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financial results for the quarter ended September 30, 2012. Corcept reported a net loss of $8.3... More...>> |
| 10/15/2012 | 9:00AM | MWUS | Corcept Therapeutics Appoints Daniel M. Bradbury to Board of Directors
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, announced today that Daniel M. Bradbury has been appointed to the Company's Board of Directors. "We are pleased... More...>> |
| 08/07/2012 | 8:35AM | MWUS | Corcept Therapeutics Announces $30 Million Synthetic, Capped Royalty Transaction; Terminates Committed Equity Financing Facil...
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today announced that it has sold to an investment fund managed by Pharmakon Advisors a synthetic capped royalty... More...>> |
| 08/07/2012 | 8:30AM | MWUS | Corcept Therapeutics Announces Second Quarter Results and Corporate Update
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic and psychiatric disorders, today reported its financial results for the quarter ended June 30, 2012. In April 2012, Corcept began offering... More...>> |
